Copertina

Artemisinins in autoimmune diseases: effects and mechanisms in systemic lupus erythematosus and rheumatoid arthritis

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Fanchao Zhou, Guoming Li, Ruixiang Tan, Guodong Wu, Changsheng Deng
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	British Journal of Pharmacology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Inter‐regional pharmacokinetics and exposure–response analyses of belimumab in patients with system lupus erythematosus
di: Junyi Wu, et al.
Pubblicazione: (2024)

Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity
di: Naïm Bouazza, et al.
Pubblicazione: (2025)

A scoping review of disease‐modifying antirheumatic drug nonadherence in rheumatoid arthritis: Measurement, prevalence and implications for clinical practice
di: Lauren Fraser, et al.
Pubblicazione: (2025)

Inflammation‐mediated drug interactions of olokizumab and cytochrome P450 activities in patients with rheumatoid arthritis
di: Svetlana Agachi, et al.
Pubblicazione: (2024)

Trajectory of lipid profiles in rheumatoid arthritis patients receiving tofacitinib: Evidence from the prospective CENTRA cohort
di: Hong Huang, et al.
Pubblicazione: (2026)

Integrative immunomodulation in systemic autoimmune diseases: Mechanistic complementarity and therapeutic strategies of traditional Chinese and conventional medicine
di: Xiaomeng Zhang, et al.
Pubblicazione: (2026)

Insight into the regulatory mechanism of β‐arrestin2 and its emerging role in diseases
di: Meng Qi, et al.
Pubblicazione: (2024)

GNS561 (ezurpimtrostat), a small basic lipophilic molecule, prevents lupus phenotype in a pristane‐induced lupus mouse model
di: Eya Toumi, et al.
Pubblicazione: (2025)

Ibuprofen inhibits human sweet taste and glucose detection implicating an additional mechanism of metabolic disease risk reduction
di: Emily C. Hanselman, et al.
Pubblicazione: (2025)

Off‐target effects of statins: molecular mechanisms, side effects and the emerging role of kinases
di: Francisco Alejandro Lagunas‐Rangel, et al.
Pubblicazione: (2024)

Fn14 signalling participates in pristane‐induced murine lupus through exacerbating oxidative stress
di: Zhu Yan, et al.
Pubblicazione: (2026)

tiRNA‐Gly‐GCC‐002 promotes epithelial‐mesenchymal transition and fibrosis in lupus nephritis via FKBP5‐mediated activation of Smad
di: Xueting Liu, et al.
Pubblicazione: (2024)

Tert‐butylhydroquinone promotes skin flap survival by inhibiting oxidative stress mediated by the Nrf2/HO‐1 signalling pathway
di: Kaitao Wang, et al.
Pubblicazione: (2024)

Caspase Recruitment Domain 6 ( CARD6) is the therapeutic target of dihydroartemisinin for lupus nephritis based on Proteolysis Targeting Chimera (PROTAC) technology
di: Honglian Li, et al.
Pubblicazione: (2026)

Reconsidering the microbial origins of primary sclerosing cholangitis and related autoimmune disorders: A case for the antro‐duodenal microbiome
di: Richard Kellermayer, et al.
Pubblicazione: (2025)

Network medicine and systems pharmacology approaches to predicting adverse drug effects
di: Alessio Funari, et al.
Pubblicazione: (2024)

Comment on ‘Renoprotective effects of dapagliflozin in diabetic patients with chronic kidney disease: A retrospective observational study’
di: Jia Chen, et al.
Pubblicazione: (2026)

Recent advances in neuroinflammation prevention and therapy: the role of natural products and underlying mechanisms based on molecular targets
di: Mei‐Mei Zhao, et al.
Pubblicazione: (2024)

A comprehensive review of anti‐colorectal cancer alkaloids from traditional Chinese medicine: Sources, chemical structures, mechanisms and therapeutic applications
di: Kaiping Cong, et al.
Pubblicazione: (2026)

A novel recombinant peptide, RGD‐Latcripin‐7A, targeting neovascularization in skin transplantation: Tissue regeneration and autophagy mechanism
di: Xuzi Zhang, et al.
Pubblicazione: (2026)

Cholinergic G protein‐coupled bile acid receptor 1 (TGR5/GPBA) in the medial septal orchestrates adult hippocampal neurogenesis and cognition in Alzheimer's disease mice
di: Rui‐Zhe Nie, et al.
Pubblicazione: (2025)

Population pharmacokinetics of long‐term hydroxychloroquine therapy in patients with rheumatic diseases
di: Chunlan Yang, et al.
Pubblicazione: (2024)

AdipoRon promotes amyloid‐β clearance through enhancing autophagy via nuclear GAPDH‐induced sirtuin 1 activation in Alzheimer's disease
di: Fengjiao Sun, et al.
Pubblicazione: (2024)

Exploring drug mechanisms through single‐cell proteomics
di: Yuzhi Sun, et al.
Pubblicazione: (2026)

Targeted peptide‐modified M2 exosomes drug delivery system for the targeted regulation of the lung injury microenvironment with isorhynchophylline (IRN): based on the inflammatory–metabolic–epigenetic synergy mechanism
di: Jin‐Ru Zou, et al.
Pubblicazione: (2026)

Resolution pharmacology and the treatment of infectious diseases
di: Vivian Vasconcelos Costa, et al.
Pubblicazione: (2024)

Role for the liver X receptor agonist 22‐ketositosterol in preventing disease progression in an Alzheimer's disease mouse model
di: Nikita Martens, et al.
Pubblicazione: (2025)

Updates on Mediterranean diet and health status: active ingredients and pharmacological mechanisms
di: Lukas Schwingshackl, et al.
Pubblicazione: (2026)

Elucidating the beneficial impact of exercise on chronic obstructive pulmonary disease and its comorbidities: Integrating proteomic and immunological insights
di: Xishuai Wang, et al.
Pubblicazione: (2024)

The cytoplasmic sensor, the AIM2 inflammasome: A precise therapeutic target in vascular and metabolic diseases
di: Jiuguo Lin, et al.
Pubblicazione: (2024)

Drug‐likeness evaluation and inhibitory mechanism of the emodin derivative on cardiac fibrosis based on metastasis‐associated protein 3
di: Heng Liu, et al.
Pubblicazione: (2025)

Circadian time‐dependent effects of experimental colitis on theophylline disposition and toxicity
di: Yi Yang, et al.
Pubblicazione: (2024)

Cannabinoid CB2 receptor‐mediated analgesia: mechanism‐based insights and therapeutic potential
di: Kelsey G. Guenther, et al.
Pubblicazione: (2025)

Renoprotective effects of dapagliflozin in diabetic patients with chronic kidney disease: A retrospective observational study
di: Sara Al Lawati, et al.
Pubblicazione: (2026)

Characterisation of cotadutide's dual GLP‐1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model
di: Rolien Bosch, et al.
Pubblicazione: (2024)

Non‐canonical PKG1 regulation in cardiovascular health and disease
di: Jie Su, et al.
Pubblicazione: (2025)

Innovative pharmacotherapy for hepatic metabolic and chronic inflammatory diseases in China
di: Feng Zhang, et al.
Pubblicazione: (2024)

Identification of drug repurposing candidates for the treatment of polycystic kidney disease
di: Alina Meyer, et al.
Pubblicazione: (2026)

Decoding fatal toxic effects in checkpoint inhibitor therapy using real‐world pharmacovigilance data and machine learning
di: Dongxue Yan, et al.
Pubblicazione: (2025)

Trained immunity: A link between risk factors and cardiovascular disease
di: Mingqi Chen, et al.
Pubblicazione: (2024)